No Data
No Data
Retail Investors Invested in Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHSE:688076) Copped the Brunt of Last Week's CN¥879m Market Cap Decline
gtja: The new signed orders for CXO in the first half of the year show a positive trend, and the API profitability is improving gradually by quarter.
In the first half of the year, CXO performance is under short-term pressure, with a positive trend in new signings; the API destocking is nearing completion, and profitability is improving quarter by quarter.
Nuotai Biology (688076.SH) distributed 0.1 yuan per share in the first half of the year, with a record date of September 9th.
Nutai Biological (688076.SH) announced that the company will distribute interim equity in the first half of 2024, with a dividend of per share...
Jiangsu Sinopep-Allsino Biopharmaceutical's H1 Profit Surges Fivefold
Jiangsu Sinopep-Allsino Biopharmaceutical: Summary of Half-Year Report in 2024.
Jiangsu Sinopep-Allsino Biopharmaceutical: Half-year report for the year 2024.
No Data
No Data